PharmaKure granted MHRA Clinical Trial Authorisation (CTA) for PK051 for the treatment of mild cognitive impairment due to Alzheimer’s Disease

  • Post author:
  • Post category:uncategorized

Clinical Trial Authorisation application granted for combined drug PK051 targeting amyloid deposits associated with Alzheimer’s Disease.

Continue ReadingPharmaKure granted MHRA Clinical Trial Authorisation (CTA) for PK051 for the treatment of mild cognitive impairment due to Alzheimer’s Disease